Project Echo for PWS

ECHO 4 PWS: Orthopedics

When: Tuesday, December 17,  2024 at 5:00 PM EST

Where: Virtual/Zoom Video
This series is for healthcare providers only

PWSA | USA's - ECHO 4 PWS Healthcare Provider Series

PWSA | USA launched our new Healthcare Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to healthcare professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.

Our next healthcare ECHO topic will take place on Tuesday, December 17, 2024, at 5:00 p.m. EST and will focus on Orthopedics and PWS presented by Dr. Harold van Bosse, followed by a 20-minute case study on PWS.

PWSA | USA’s Healthcare Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.

While this ECHO series is only for healthcare providers to attend, recordings of the webinars are available for our PWS families to view HERE.

Scroll below to find more ECHO 4 PWS webinar opportunities.

Speaker

Harold van Bosse, MD

For almost 30 years, Dr. Harold van Bosse has been treating the entire realm of pediatric orthopedic conditions, with special interests in limb deformity, neuromuscular disease, and pediatric spine deformities. His practice is mostly devoted to two conditions: arthrogryposis multiplex congenita (AMC) and Prader-Willi syndrome (PWS). Dr. van Bosse has developed novel procedures to address hip and knee contractures, as well as to advance the minimally operative correction of foot deformities for AMC. For PWS, he focused on the least invasive modalities that will preserve spinal growth and chest development in the very young children with scoliosis.

ECHO 4 PWS is Sponsored By

Soleno

LEarn More about PWS Research

Aardvark Therapeutics Shares Additional Details on Voluntary Pause of HERO Clinical Trial

Aardvark Therapeutics Shares Additional Details on Voluntary Pause of HERO Clinical Trial

Last month, we shared that Aardvark Therapeutics announced a voluntary pause in enrollment and dosing for the Phase 3 HERO clinical trial evaluating ARD-101 for hyperphagia in individuals with Prader-Willi syndrome (PWS). In a new update, Aardvark has provided additional details to help explain this decision and outline next steps. According to the announcement shared […]

Important Update for the PWS Community: HERO Phase 3 Trial for ARD-101 Voluntarily Paused

Important Update for the PWS Community: HERO Phase 3 Trial for ARD-101 Voluntarily Paused

We would like to share an important update from Aardvark Therapeutics. Aardvark has announced a voluntary pause of the Phase 3 HERO clinical trial, which is evaluating ARD‑101 for the treatment of hyperphagia in people with Prader‑Willi syndrome. The decision to pause the trial is based on reversible cardiac observations identified in a non-PWS, separate healthy […]

PWSA | USA’s 2025 Research Year in Review

PWSA | USA’s 2025 Research Year in Review

The year 2025 marked an extraordinary period of progress, collaboration, and momentum for PWSA | USA’s Medical and Research pillar. One of the most historic milestones for the PWS community occurred in March 2025 with the FDA approval of the first medication specifically indicated for the treatment of hyperphagia in individuals with PWS. This landmark […]

Scroll to top